HOME > BUSINESS > Suven Life Sciences gets two product patents in India and Japan

Suven Life Sciences gets two product patents in India and Japan

suvenDrug manufacturer Suven Life Sciences Ltd said it got two product patents in India and Japan for to a new compound for the treatment of disorders associated with Neurodegenerative diseases.

The patents are valid through 2026-2032.

The granted claims include a class of selective 5-HT6 compounds and H3 inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders. Earlier this month, the company announced it had got similar patents in three countries.

According to the U.S. Food and Drug Administration, a new chemical entity (NCE) is a drug that contains no active moiety that has been approved by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act.

Neurodegeneration is the umbrella term for the progressive loss of structure or function of neurons, including death of neurons. Many neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s, and Huntington’s occur as a result of neurodegenerative processes.

With these new patents, Suven has a total of nineteen granted patents from India and Japan each.

“The grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” said Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing pharmaceutical products, which are class CNS therapies through the use of GPCR targets.

Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer’s disease and Schizophrenia. In addition, the Company has ten internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.

Follow ULTRA.news
Strides Shasun to launch allergy drug in the US Pharma company Strides Shasun said it had received approval allergy drug Cetirizine Hydrochloride in the US."The US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 mln, with only one other generic player," the company said."The product is re...
Glenmark Pharma gets UK OTC approval for anti-malarial medicine Glenmark Pharmaceuticals said it received approval from UK authorities for to sell its Maloff Protect anti-malarial medication without prescription.It contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK.The Me...
Sun Pharma selects Samsung to manufacture psoriasis drug Sun Pharma said it has inked a long-term agreement with Samsung BioLogics under which the Korean company will manufacture Tildrakizumab, a potential treatment for plaque psoriasis, for the Indian company.Plaque psoriasis is an autoimmune condition which results in patches of ...
Strides Shasun gets USFDA nod for nausea drug Pharmaceutical company Strides Shasun said it received approval from the United States Food & Drug Administration to sell nausea drug Promethazine Hydrochloride in the country.The US market for Promethazine Hydrochloride tablets is approximately USD 17 Million.It will be ...
Unichem Labs says USFDA completes inspection of Goa facility Unichem Laboratories said the US FDA has completed its inspection of the company's formulations manufacturing facility in Goa.Unichem Labs' formulations plant in GoaThe facility has received an Establishment Inspection Report, the company added."This receipt indica...
Zydus Cadila gets approval for obesity drug in USA Zydus Cadila said it received the final approval from the US FDA to market obesity drug Phentermine Hydrochloride.The drug will be marketed in the form of orally disintegrating tablets in strengths of 15 mg, 30 mg, and 37.5 mg.The drug is used to treat obesity in people w...
Zydus Cadila gets nod to sell ADHD drug in USA Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals received final approval from the US Food and Drug Administration to sell generic drug Dextroamphetamine Sulfate.Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyp...
Zydus Cadila gets USFDA nod for Hepatitis B drug Zydus Cadila has received the final approval from the the US Food and Drug Administration to market Hepatitis B drug Entecavir.The drug has sales of $166.3 million in the US, and will be sold in 0.5 mg and 1 mg dosage.It will be produced at the group's formulations manufa...
Glenmark gets USFDA approval for generic joint-pain drug in US Glenmark Pharmaceuticals said it received final approval from the United States Food & Drug Administration for marketing a generic version of joint-pain drug Indocin of Iroko Pharmaceuticals.The drug has annual sales of approximately $6.3 million.With this, Glenmark’s ...
Lupin launches skin ointment in the US Pharma Major Lupin said it launched Desoximetasone cream for treating skin problems in the US market.The company had received approvals from the US Food and Drug Administration earlier.The drug is the generic equivalent of Tarot Pharma's Topicort, which had US sales of $...
Alembic Pharma to launch generic version of AstraZeneca heart drug in USA Alembic Pharmaceuticals said it received approval from the US Food & Drug Administration for selling a generic equivalent of AstraZeneca's heart drug Atacand.Approval was granted for the sale of candesantan cilexetil in the dosage of 32 mg.Candesartan cilexetil is used ...
Glenmark Pharma buy rights to cancer drug from US firm Glenmark Pharmaceuticals said it entered into a licensing agreement with Boston-based biopharmaceutical company APC Therapeutics Inc for exclusive rights for a cancer drug.The agreement covers a small molecule based on Antigen Presenting Cell (APC) biology, the Indian compa...
Zydus Cadila gets USFDA approval for generic version of popular migraine drug Zydus Cadila said it received final approval from the US Food and Drug Administration to market migraine drug Eletriptan Hydrobromide in the US.The drug is currently marketed and manufactured by Pfizer Inc and sold in the US and Canada under the brand name Relpax.The two...
Lupin launches generic antidepressant in the US India's second biggest pharmaceutical company Lupin said it has launched the generic version of Valeant's Wellbutrin antidepressant tablet Wellbutrin XL in the US.Wellbutrin XL tablet has yearly US sales of USD 758 million or about Rs 5,000 cr.It is used for the treatment...
Aurobindo Pharma launches kidney drug in the US Aurobindo Pharma said it received final approval from the US Food & Drug Administration to manufacture generic version of kidney drug Renvela from Genzyme.Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm is being launched immediately, the company said.The drug had ...
Lupin gets USFDA approval for pain relief drug Pharma Major Lupin said received final approval for launching a generic version of Mallinckrodt Inc.'s Roxicodone Tablets in the United States.The drug is used for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are...
Suven Life Sciences gets US, Australia patent for CNS molecule Suven Life Sciences Ltd said it got a patent from Australia and another from the US for a new molecule used for treating disorders associated with Neurodegenerative diseases.The 'new chemical entity' patent no 2014358652 from Australia is valid through 2032, while that from ...
Unichem Labs Ghaziabad plant inspected by USFDA Generic drug manufacturer Unichem Laboratories said its formulations manufacturing facility at Ghaziabad has successfully exited an inspection by the US Food and Drug Administration.Inside a Unichem plantIt received an Establishment Inspection Report (EIR) from the USFDA...
Zydus Cadila gets USFDA approval for generic form of colitis drug Lialda Zydus Cadila said the US Food and Drug Administration has given the final approval to market the company's Mesalamine Delayed-Release Tablets in the US market.Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda.L...
Strides Shasun gets USFDA approval for ibuprofen Pharmaceuticals manufacturer Strides Shasun said it received approval from the United States Food & Drug Administration (USFDA) for ibuprofen Tablets 200 mg for over the counter sales.According to Ri data, the US market for ibuprofen Tablets USP 200 mg (OTC) is approximately...
Trademark registration up three fold in India National Institute of Intellectual Property Mgmt, DelhiThe number of trademarks awarded by the India's Controller General of Patents, Designs & Trade Marks has jumped threefold this financial year, according to data obtained from the Patent Office.A total of 2.11 lak...
Nokia files more patent infringement suits against Apple Nokia has filed further complaints alleging that Apple products infringe a number of Nokia patents, expanding its litigation originally announced on December 21. Across actions in 11 countries, there are now 40 patents in suit, which cover technologies such as display, us...
Govt of India starts crack down on low-quality medicine makers The government of India has started conducting inspections at drug manufacturing units across the country to prevent the production of low-quality drugs and medicines in India.Typically, inspections are conducted by state authorities, while central agencies largely confin...
Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been termi...
Bliss GVS Healthcare wins three-year contract worth Rs 760 cr from Kenya Bliss GVS Healthcare Ltd said it won a three year contract worth $111.40 mln (Rs 760 cr) from Aon Kenya Insurance Brokers Ltd for provision of medical health care services in Kenya. Bliss GVS Pharma Ltd is a pharmaceutical company based in Mumbai, India.Bliss GVS...